ASH 2022 | Results from a Phase I study of CC-98633 in R/R myeloma
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, shares some results from a Phase I study evaluating CC-98633, a next-generation BCMA-targeting CAR-T cell therapy, in patients with relapsed/refractory (R/R) multiple myeloma (NCT04394650). Dr Costa first highlights the NEX-T manufacturing process used to develop this agent, and then discusses the activity and safety of this agent as demonstrated in the study. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Sanofi: Consultancy, Honoraria; Adaptive Biotechnologies: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Genentech: Research Funding; AbbVie: Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding.
